Articles

The Effect of Nanogold-Nanosilver to Boost Immunity in People Affected (Reactive and Positive) by Covid-19

/in /by

COVID-19 virus outbreak was first found in Wuhan China. The current COVID-19 is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-CoV-2). The interaction of the virus with the immune system causes the immunity of people affected by the outbreak to decrease. The combination of nanogold and nanosilver, that is an antimicrobial and antiviral agent, can inhibit the replication of the COVID-19 virus an d act as drug delivery. This research aims to determine the effect of nanogold-nanosilver that can increase immunity in people who are positively affected by the COVID-19 virus. The method used in this research was quantitative descriptive by describing the effect of the nanogold-nanosilver health drink given to increasing human immunity exposed to the COVID-19 virus seen from the number of respondent cures. The respondents consumed 500 mL of health drinks containing nanogold and nanosilver compounds with a concentration of 2 ppm per day. Based on the data obtained, the combination of nanogold and nanosilver could increase the immunity of people affected by COVID-19, marked by physical changes that became healthier, fitter and negative swab test results and accelerate the healing of COVID-19 patients.

Formulation Development, Characterization and In Vitro Antibacterial Activity Evaluation of Cefazolin Loaded Mesoporous Silica Nanoparticles

/in /by

The main aims of this manuscript are to: i) investigate the high drug loading of cefazolin and its characterization, ii), demonstrate the bioactivity of the cefazolin particles in vitro on Staphylococcus aureus. From our results, it is observed that the cefazolin loading into MCM-41 particles is 34 wt %. Furthermore, particles showed the burst release of cefazolin at pH 6.8.  At higher concentration, MCM-41 particles are comparatively more cytotoxic as compared to lower concentration. Finally, cefazolin loaded particles showed higher in vitro antibacterial activity against Staphylococcus aureus as compared to cefazolin only.